Heart-Drug Study Reverts to Original Path
Posted on: Monday, 17 December 2007, 12:00 CST
Two pharmaceutical companies reversed plans to change direction in a heart-drug study of Vytorin and they're back to the original course.
Officials last month said they planned to change the statistical analysis of a jointly sponsored study of Vytorin, a drug that combines two anti-high-cholesterol drugs -- Merck & Co.'s Zocor and Schering-Plough's Zetia, the Wall Street Journal reported. The study aims to determine if the drugs combined make the now-off-patent Zocor more effective.
If Zocor is more effective in combination, insurers would be more inclined to approve $3-a-day Vytorin than cheaper, generic forms of Zocor, the Journal said.
Study results are expected in March.
Source: United Press International
Related Articles
- Data Recently Published in Mayo Clinic Proceedings Showed VYTORIN(R) (Ezetimibe/Simvastatin) Superior to Lipitor (Atorvastatin) in Reducing LDL ''Bad'' Cholesterol in Patients With Type II Diabetes at the Dose Comparisons Studied
- REPEAT/New Study Showed VYTORIN(R) (Ezetimibe/Simvastatin) Significantly More Effective Than Crestor(R) (Rosuvastatin) at Lowering LDL ''Bad'' Cholesterol At All Doses Compared
- New Study Showed VYTORIN(R) (Ezetimibe/Simvastatin) Significantly More Effective Than Crestor(R) (Rosuvastatin) at Lowering LDL ''Bad'' Cholesterol At All Doses Compared
- REPEAT/New Study Showed VYTORIN(R) (Ezetimibe/Simvastatin) Superior to Lipitor in Reducing LDL ''Bad'' Cholesterol in Patients With Type II Diabetes at the Recommended Usual Starting Doses
- New Study Showed VYTORIN(R) (Ezetimibe/Simvastatin) Superior to Lipitor in Reducing LDL ''Bad'' Cholesterol in Patients With Type II Diabetes at the Recommended Usual Starting Doses
- Data Analysis Showed VYTORIN(R) (Ezetimibe/Simvastatin) Significantly Reduced LDL ''Bad'' Cholesterol and C-Reactive Protein (CRP) in Patients With High Cholesterol Compared to Zocor(R) (Simvastatin)
- New Analysis in Patients With Type 2 Diabetes From Trial With VYTORIN-TM- -Ezetimibe/Simvastatin- Presented at ADA; Consistent With Overall Study Which Showed Superior LDL Cholesterol Reduction With VYTORIN Versus Lipitor
- Study Showed VYTORIN-TM- -Ezetimibe/Simvastatin- Superior to Lipitor at Lowering LDL -Bad- Cholesterol
- Merck/Schering-Plough Pharmaceuticals Announces New Clinical Trial for VYTORIN -Ezetimibe/Simvastatin-
 |
 |
User Comments (0)
RSS Feeds